Compare Organon & Co. Common Stock (OGN) vs Smurfit WestRock plc Ordinary Shares (SW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Smurfit WestRock plc Ordinary Shares — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Smurfit WestRock plc Ordinary Shares trades at $40.75 (market cap $21.74B). The key difference: Smurfit WestRock plc Ordinary Shares is far larger — about 6× Organon & Co. Common Stock's market cap, and Smurfit WestRock plc Ordinary Shares pays the higher dividend (4.36%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Smurfit WestRock plc Ordinary Shares for 5 Days on average.
| OGN | SW | |
|---|---|---|
Market Cap | $3.62B | $21.74B |
Volume | 2,892,999 | 2,458,317 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $51.84 |
52-Week Low | $5.70 | $32.79 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $11.04B | $35.23B |
Dividend Yield | 0.58% | 4.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Smurfit Westrock (SW) trades at $41.45, showing modest daily gains of 0.93% but facing technical bearish signals with 17 sell indicators versus 4 buys. The company reported three consecutive quarterly earnings misses amid cost pressures, though revenue remains stable above $31 billion. Recent strategic moves include the $420 million acquisition of CMPC's Chilean containerboard business to strengthen regional footprint and reduce costs.
Despite unanimous analyst buy ratings and a $71.50 price target suggesting 72% upside, SW faces execution risks from freight cost inflation and margin compression. The stock's high P/E ratio of 44.01 contrasts with weak profitability metrics (ROE 2.74%), creating a divergence between valuation and fundamental performance that warrants cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Smurfit WestRock plc Ordinary Shares
Smurfit WestRock plc is an Ireland-headquartered packaging company that manufactures corrugated containers and consumer packaging from containerboard and paperboard, operating mills, converting plants, and recycling facilities across more than 40 countries.
Read more on SW →
